Lancet Respiratory Medicine最新文献

筛选
英文 中文
Managing tuberculosis before the onset of symptoms 在肺结核症状出现前进行治疗
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2024-11-11 DOI: 10.1016/s2213-2600(24)00372-2
Dennis Falzon, Cecily Miller, Irwin Law, Katherine Floyd, Nimalan Arinaminpathy, Matteo Zignol, Tereza Kasaeva
{"title":"Managing tuberculosis before the onset of symptoms","authors":"Dennis Falzon, Cecily Miller, Irwin Law, Katherine Floyd, Nimalan Arinaminpathy, Matteo Zignol, Tereza Kasaeva","doi":"10.1016/s2213-2600(24)00372-2","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00372-2","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":76.2,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142598522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis. 针对囊性纤维化的同情使用试验和公平获得变异特异性治疗。
IF 38.7 1区 医学
Lancet Respiratory Medicine Pub Date : 2024-11-01 Epub Date: 2024-08-13 DOI: 10.1016/S2213-2600(24)00243-1
Katherine Odem-Davis, Jennifer L Taylor-Cousar
{"title":"Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis.","authors":"Katherine Odem-Davis, Jennifer L Taylor-Cousar","doi":"10.1016/S2213-2600(24)00243-1","DOIUrl":"10.1016/S2213-2600(24)00243-1","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":38.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership. 败血症研究的十大研究重点:英国詹姆斯-林德联盟优先事项设定伙伴关系。
IF 38.7 1区 医学
Lancet Respiratory Medicine Pub Date : 2024-11-01 Epub Date: 2024-09-12 DOI: 10.1016/S2213-2600(24)00298-4
Joanne McPeake, Mark Oakes, Colin Graham, Nahid Ahmad, Nazir Lone, Bronwen Connolly
{"title":"Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership.","authors":"Joanne McPeake, Mark Oakes, Colin Graham, Nahid Ahmad, Nazir Lone, Bronwen Connolly","doi":"10.1016/S2213-2600(24)00298-4","DOIUrl":"10.1016/S2213-2600(24)00298-4","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":38.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study. 非小细胞肺癌中的抗 CTLA-4:NIPPON 研究的启示。
IF 38.7 1区 医学
Lancet Respiratory Medicine Pub Date : 2024-11-01 Epub Date: 2024-08-16 DOI: 10.1016/S2213-2600(24)00218-2
Molly S C Li, Stephanie P L Saw, Alfredo Addeo
{"title":"Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study.","authors":"Molly S C Li, Stephanie P L Saw, Alfredo Addeo","doi":"10.1016/S2213-2600(24)00218-2","DOIUrl":"10.1016/S2213-2600(24)00218-2","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":38.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142005806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Easing the stress of chronic cough. 缓解慢性咳嗽的压力
IF 38.7 1区 医学
Lancet Respiratory Medicine Pub Date : 2024-11-01 Epub Date: 2024-08-30 DOI: 10.1016/S2213-2600(24)00254-6
Marta Dąbrowska, Lorcan McGarvey
{"title":"Easing the stress of chronic cough.","authors":"Marta Dąbrowska, Lorcan McGarvey","doi":"10.1016/S2213-2600(24)00254-6","DOIUrl":"10.1016/S2213-2600(24)00254-6","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":38.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142121127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial. 吉法匹克对慢性咳嗽和咳嗽引起的压力性尿失禁妇女的疗效和安全性:3b 期随机、多中心、双盲、安慰剂对照试验。
IF 38.7 1区 医学
Lancet Respiratory Medicine Pub Date : 2024-11-01 Epub Date: 2024-08-30 DOI: 10.1016/S2213-2600(24)00222-4
Surinder S Birring, Linda Cardozo, Roger Dmochowski, Peter Dicpinigaitis, Amna Afzal, Carmen La Rosa, Susan Lu, Allison Martin Nguyen, Ruji Yao, Paul A Reyfman
{"title":"Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial.","authors":"Surinder S Birring, Linda Cardozo, Roger Dmochowski, Peter Dicpinigaitis, Amna Afzal, Carmen La Rosa, Susan Lu, Allison Martin Nguyen, Ruji Yao, Paul A Reyfman","doi":"10.1016/S2213-2600(24)00222-4","DOIUrl":"10.1016/S2213-2600(24)00222-4","url":null,"abstract":"<p><strong>Background: </strong>Approximately two-thirds of women with chronic cough have cough-induced stress urinary incontinence (CSUI). We aimed to evaluate the efficacy and safety of gefapixant in reducing CSUI episodes in women with refractory or unexplained chronic cough.</p><p><strong>Methods: </strong>This phase 3b, double-blind, randomised, placebo-controlled trial done at 90 sites in 12 countries enrolled women aged 18 years or older who had chronic cough for at least 1 year, a diagnosis of refractory or unexplained chronic cough, a cough severity visual analogue scale score of 40 mm or more (100 mm maximum), and CSUI for 3 months or more. Participants were randomised 1:1 to oral gefapixant or placebo for 12 weeks. The primary outcome was percentage change from baseline in daily CSUI episodes (7-day average) at week 12. This study is registered with ClinicalTrials.gov (NCT04193176).</p><p><strong>Findings: </strong>From May 10, 2020, to Sept 2, 2022, 375 participants were randomised to and treated with gefapixant 45 mg twice daily (n=185) or placebo (n=190). Mean age was 56·4 years (SD 11·4), with mean chronic cough duration of 5·2 years (SD 6·6) and SUI duration of 4·0 years (SD 5·9). Least-squares mean percentage change from baseline in daily CSUI episodes was -52·8% (95% CI -58·4 to -47·1%) for gefapixant and -41·1% (-46·7 to -35·4%) for placebo (estimated treatment difference: -11·7% [95% CI -19·7 to -3·7]; p=0·004). 129 (70%) of 185 participants who received gefapixant and 71 (37%) of 190 participants who received placebo had at least one adverse event. Safety and tolerability were consistent with previous trials of gefapixant; the most frequent adverse events were taste related.</p><p><strong>Interpretation: </strong>Gefapixant 45 mg twice daily is the first treatment to show efficacy versus placebo in reducing CSUI episodes in participants with refractory or unexplained chronic cough.</p><p><strong>Funding: </strong>Merck Sharp & Dohme, a subsidiary of Merck & Co.</p>","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":38.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142121128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking bronchiectasis as an inflammatory disease. 重新思考支气管扩张症这种炎症性疾病。
IF 38.7 1区 医学
Lancet Respiratory Medicine Pub Date : 2024-11-01 Epub Date: 2024-07-03 DOI: 10.1016/S2213-2600(24)00176-0
Merete B Long, Sanjay H Chotirmall, Michal Shteinberg, James D Chalmers
{"title":"Rethinking bronchiectasis as an inflammatory disease.","authors":"Merete B Long, Sanjay H Chotirmall, Michal Shteinberg, James D Chalmers","doi":"10.1016/S2213-2600(24)00176-0","DOIUrl":"10.1016/S2213-2600(24)00176-0","url":null,"abstract":"<p><p>Bronchiectasis is understood to be the result of a complex interaction between infection, impaired mucociliary clearance, inflammation, and lung damage. Current therapeutic approaches to bronchiectasis are heavily focused on management of infection along with enhancing mucus clearance. Long-term antibiotics have had limited success in clinical trials, suggesting a need to re-evaluate the concept of bronchiectasis as an infective disorder. We invoke the example of asthma, for which treatment paradigms shifted away from targeting smooth muscle constriction, towards permanently suppressing airway inflammation, reducing risk and ultimately inducing remission with precision anti-inflammatory treatments. In this Review, we argue that bronchiectasis is primarily a chronic inflammatory disease, requiring early identification of at-risk individuals, and we introduce a novel concept of disease activity with important implications for clinical practice and future research. A new generation of novel anti-inflammatory treatments are under development and repurposing of anti-inflammatory agents from other diseases could revolutionise patient care.</p>","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":38.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fatal dyspnoea at the Palace of Versailles. 凡尔赛宫致命的呼吸困难。
IF 38.7 1区 医学
Lancet Respiratory Medicine Pub Date : 2024-11-01 Epub Date: 2024-08-16 DOI: 10.1016/S2213-2600(24)00270-4
Emmanuel Drouin, Serge Wasersztrum, Arnaud Chambellan
{"title":"Fatal dyspnoea at the Palace of Versailles.","authors":"Emmanuel Drouin, Serge Wasersztrum, Arnaud Chambellan","doi":"10.1016/S2213-2600(24)00270-4","DOIUrl":"10.1016/S2213-2600(24)00270-4","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":38.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142005820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review. 呼吸道合胞病毒与肺炎链球菌在儿童呼吸道感染发病机制中的相互作用:系统综述。
IF 38.7 1区 医学
Lancet Respiratory Medicine Pub Date : 2024-11-01 Epub Date: 2024-07-08 DOI: 10.1016/S2213-2600(24)00148-6
Sjanna B Besteman, Debby Bogaert, Louis Bont, Asuncion Mejias, Octavio Ramilo, Daniel M Weinberger, Ron Dagan
{"title":"Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review.","authors":"Sjanna B Besteman, Debby Bogaert, Louis Bont, Asuncion Mejias, Octavio Ramilo, Daniel M Weinberger, Ron Dagan","doi":"10.1016/S2213-2600(24)00148-6","DOIUrl":"10.1016/S2213-2600(24)00148-6","url":null,"abstract":"<p><p>Lower respiratory tract infections, commonly caused by respiratory syncytial virus (RSV) or Streptococcus pneumoniae (pneumococcus), pose a substantial global health burden, especially in children younger than 5 years of age. A deeper understanding of the relationship between RSV and pneumococcus would aid the development of health-care approaches to disease prevention and management. We completed a systematic review to identify and assess evidence pertaining to the relationship between RSV and pneumococcus in the pathogenesis of childhood respiratory infections. We found mechanistic evidence for direct pathogen-pathogen interactions and for indirect interactions involving host modulation. We found a strong seasonal epidemiological association between these two pathogens, which was recently confirmed by a parallel decrease and a subsequent resurgence of both RSV and pneumococcus-associated disease during the COVID-19 pandemic. Importantly, we found that pneumococcal vaccination was associated with reduced RSV hospitalisations in infants, further supporting the relevance of their interaction in modulating severe disease. Overall evidence supports a broad biological and clinical interaction between pneumococcus and RSV in the pathogenesis of childhood respiratory infections. We hypothesise that the implementation of next-generation pneumococcal and RSV vaccines and monoclonal antibodies targeting RSV will act synergistically to reduce global morbidity and mortality related to childhood respiratory infections.</p>","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":38.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New thinking and a new direction in bronchiectasis. 支气管扩张症的新思维和新方向。
IF 38.7 1区 医学
Lancet Respiratory Medicine Pub Date : 2024-11-01 Epub Date: 2024-08-20 DOI: 10.1016/S2213-2600(24)00244-3
Ian D Pavord
{"title":"New thinking and a new direction in bronchiectasis.","authors":"Ian D Pavord","doi":"10.1016/S2213-2600(24)00244-3","DOIUrl":"10.1016/S2213-2600(24)00244-3","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":38.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信